{"id":"m108-monoclonal-antibody","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a monoclonal antibody in phase 3 development by FutureGen Biopharmaceutical, M108 is designed to modulate immune responses or directly target cancer cells. The exact molecular target and mechanism require further clarification from clinical trial data, but monoclonal antibodies in oncology typically work by blocking inhibitory signals on immune cells or directly engaging tumor antigens.","oneSentence":"M108 is a monoclonal antibody that targets a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or block pathogenic signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:58.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07383922","phase":"PHASE3","title":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2026-02-28","conditions":"Pancreatic Cancer","enrollment":524},{"nctId":"NCT06177041","phase":"PHASE3","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","status":"RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2023-12-25","conditions":"Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":486},{"nctId":"NCT04894825","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China","status":"UNKNOWN","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2021-06-11","conditions":"Advanced Unresectable Solid Tumors","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"M108 monoclonal antibody","genericName":"M108 monoclonal antibody","companyName":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","companyId":"futuregen-biopharmaceutical-beijing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}